Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes.
about
Management of Type 1 Diabetes in PregnancyInvestigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic reviewMaternal pravastatin prevents altered fetal brain development in a preeclamptic CD-1 mouse model.The Role of Statins in Prevention of Preeclampsia: A Promise for the Future?Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse modelPreeclampsia: animal models for a human cureConsidering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefitsStatin use during pregnancy: a systematic review and meta-analysis.Teratogenic risk of statins in pregnancy.Statins and congenital malformations: cohort studyPrevention of pulmonary hypoplasia and pulmonary vascular remodeling by antenatal simvastatin treatment in nitrofen-induced congenital diaphragmatic herniaEvidence for statin therapy in polycystic ovary syndrome.Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trialPravastatin for the prevention of preeclampsia in high-risk pregnant women.Transplacental transfer and distribution of pravastatin.Cardiac drug use in pregnancy: safety, effectiveness and obstetric implications.Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments.Statins and pregnancy: between supposed risks and theoretical benefits.Assaying embryotoxicity in the test tube: current limitations of the embryonic stem cell test (EST) challenging its applicability domain.The role of maternal-fetal cholesterol transport in early fetal life: current insights.Involvement of the heme oxygenase system in the development of preeclampsia and as a possible therapeutic target.Use and impact of cardiac medication during pregnancy.Statins as Targeted "Magical Pills" for the Conservative Treatment of Endometriosis: May Potential Adverse Effects on Female Fertility Represent the "Dark Side of the Same Coin"? A Systematic Review of Literature.Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?Pravastatin Effects on Placental Prosurvival Molecular Pathways in a Mouse Model of Preeclampsia.Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability.Therapeutic Roles of Statins in Gynecology and Obstetrics: The Current Evidence.Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models.Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss.Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
P2860
Q26747535-82AC21E1-A1DC-44A2-8DF7-EA30F9E3091AQ28078252-B159F87A-7658-4D32-B065-94D366D7FE2CQ30833322-B947378E-899E-448A-B32C-E80A2797C36EQ33639463-7864C50C-0FB4-41FD-BC30-ED5D813285E7Q34533751-B90A37DE-BC36-4EC2-8DEC-7A974A2B67FBQ34534002-B568483D-8A59-4DB1-BA7E-5A8EA6103ACDQ34566253-E23A5279-D38A-4979-B93A-C17D1E1E7D1BQ34636432-8D0561BE-ACDE-458E-8CEA-9BADA9CC6417Q34643449-C871B902-FA85-4F9D-9F71-1BA65A01604EQ35184473-BC6A04CB-BD7C-4C06-95B2-CBAA96D779D1Q35275342-8D784F3A-F1EE-4218-B916-A7601BEA71A2Q36327934-BBF719D8-F2EC-44CB-B00B-AAC4348ECACFQ36945433-EC1D9C79-2EE2-41FA-99C5-A94D62B629B4Q37432893-4CB10A28-7B26-40C3-B826-EADDA5023E28Q37478894-1728B230-D35B-4C79-AC5A-7DB12F0CCFE6Q37642833-9C59D232-6E71-4957-A334-21FA37A6948DQ37830049-14540284-862D-4AB4-9FD0-BFCC5B0B3B27Q38000338-5063100E-C749-44CC-B1B7-672127C683EAQ38003481-1F0A9AF4-D12C-4271-A129-0CE017A0F5D6Q38059934-FAE54BFD-9F75-485A-8235-5E6FEEB054E4Q38284366-DEE90B71-A9B8-4262-A9AC-CDD15038C730Q38326668-02ACCEF6-C4A1-4484-8AC5-3058CAA9F772Q38451749-9E10C20F-CED4-4009-AA2D-24C92F6A17B9Q39139549-74A4C2EE-0DA9-4823-B31A-B263D7B9005AQ39773129-51068167-2A15-422C-B4FD-2D41F7A26115Q44548364-78D4875A-F3FA-4C2C-A086-D56FE200F103Q48211697-8030520A-F3DB-44B6-BD6A-21107D4134D7Q48268967-3BC78F48-EAC3-4E1B-94E7-47F757E5A11EQ49941064-17C17302-499B-41B7-B5EA-105013FF6DD1Q50905321-C21FA6FF-F289-4F79-8452-4E9FAF08BA3BQ52885913-20260C2B-0914-4383-A3FE-B3910178499B
P2860
Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@en
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@nl
type
label
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@en
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@nl
prefLabel
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@en
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@nl
P2093
P1476
Prenatal exposure to HMG-CoA r ...... n fetal and neonatal outcomes.
@en
P2093
Akiko Hosokawa
Angela Yating Ying
Evelyn T Rubin
Gideon Koren
Jacquelyn Choi
Myla E Moretti
Nobuko Taguchi
Shinya Ito
P304
P356
10.1016/J.REPROTOX.2008.06.009
P577
2008-07-01T00:00:00Z